Related Experiment Video

Updated: Jun 2, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer

Euan A Stronach1, Albandri Alfraidi, Nona Rama

  • 1Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Edinburgh, United Kingdom. e.stronach@imperial.ac.uk

Cancer Research
|May 17, 2011
PubMed

Insights

Platinum chemotherapy resistance in ovarian cancer is a major challenge. This study identifies histone deacetylase 4 (HDAC4) as a key driver of resistance by promoting STAT1 deacetylation, suggesting HDAC4 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer often develops resistance to platinum chemotherapy, limiting treatment efficacy.
  • Pre-existing resistant clones suggest selection, not generation, of resistance during treatment.
  • Understanding molecular mechanisms of acquired resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To compare paired models of platinum-sensitive and resistant ovarian cancer to identify molecular drivers of resistance.
  • To investigate the role of histone deacetylase 4 (HDAC4) and STAT1 in platinum resistance.

Main Methods:

  • Transcriptional analysis of matched ovarian cancer cell lines before and after platinum resistance development.
  • Gene knockdown experiments to assess the impact of specific genes on platinum sensitivity.
  • Analysis of paired tumor biopsies to correlate gene expression with clinical resistance.

Main Results:

  • Identified common up- and down-regulated genes in acquired platinum resistance.
  • Knockdown of HDAC4, FOLR2, PIK3R1, or STAT1 enhanced platinum-induced apoptosis in resistant cells.
  • HDAC4 physically interacts with STAT1, and HDAC4 overexpression in resistant cells correlates with STAT1 deacetylation and reduced sensitivity.
  • Increased HDAC4 expression was observed in resistant ovarian tumors compared to sensitive counterparts.

Conclusions:

  • HDAC4 overexpression promotes platinum resistance in ovarian cancer by deacetylating STAT1, leading to enhanced cancer cell survival.
  • HDAC4 is a potential therapeutic target to overcome platinum resistance in ovarian cancer.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...